×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: Health Topics | fda | spinal muscular atrophy

First Oral Drug for Spinal Muscular Atrophy Approved

the genentech headquarters in san francisco
(Andreistanescu/Dreamstime.com)

Monday, 31 August 2020 09:56 AM

The U.S. Food and Drug Administration has approved the first oral, at-home drug for spinal muscular atrophy (SMA), the agency announced Friday.

Evrysdi (risdiplam) was approved to treat patients ages 2 months and older with SMA and is the third drug approved for the disease. The drug is administered daily at home by mouth or feeding tube.

Approval was based on two clinical studies, including FIREFISH, an open-label study of 21 patients aged 6.7 months on average at study initiation. At one year, 41 percent of patients met the efficacy end point of sitting independently for more than five seconds, and at nearly two years, 81 percent of patients were alive without permanent ventilation, which the FDA notes is a "noticeable improvement from typical disease development without treatment."

In the second study, SUNFISH, a randomized, placebo-controlled study of 180 patients ages 2 to 25 years, the Motor Function Measure-32 total score increased an average of 1.36 from baseline to one year for patients randomly assigned to Evrysdi compared with a decrease of 0.19 for patients randomly assigned to placebo.

The most commonly reported side effects of Evrysdi were fever, diarrhea, rash, ulcers in the mouth area, arthralgia, and urinary tract infections. Patients with infantile-onset SMA had additional side effects of upper respiratory tract infection, pneumonia, constipation, and vomiting. The FDA warns that patients taking Evrysdi should avoid taking it with drugs that are multidrug and toxin extrusion substrates because Evrysdi may increase plasma concentrations.

Approval was granted to Genentech.

© HealthDay


FDA-Approved-Drugs
The U.S. Food and Drug Administration has approved the first oral, at-home drug for spinal muscular atrophy (SMA), the agency announced Friday.
fda, spinal muscular atrophy
249
2020-56-31
Monday, 31 August 2020 09:56 AM
Newsmax Media, Inc.
Join the Newsmax Community
Register To Comment Login To Comment
Please review Community Guidelines before posting a comment.
 
Find Your Condition
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved